Obsessive-Compulsive Disorder
Conditions
Brief summary
This is a single-center study about patients with severe resistant OCD. Main assumption is that performing 10 tDCS sessions with the anode positioned at the level of the right orbitofrontal cortex, and the cathode at the level of the supplementary motor area, associated with the provocation of symptoms before each session is effective in the reduction in obsessive-compulsive symptoms. After the inclusion visit, the treatment period is provided from D1 to D12 (one session per day from Monday to Friday, for two consecutive weeks, i.e. a total of ten sessions). Each tDCS session lasts 30 minutes at an intensity of 2 mA and is preceded by symptom provocation using a standardized procedure performed by trained personnel. The patients are then assessed on D42 and D102 (i.e. 1 month and 3 months after the end of the tDCS sessions).
Interventions
BEHAVIORALtDCS + symptoms provocation
The treatment consists of 10 sessions of tDCS. Each tDCS session lasts 30 minutes at an intensity of 2mA and is preceded by a provocation of symptoms.
Sponsors
Centre Hospitalier Henri Laborit
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patient suffering from OCD evolving for at least 2 years diagnosed according to DSM-V criteria; * Patient with good insight, defined by a score less than or equal to 18 at the threshold of delusions on the BABS (Brown Assessment of Beliefs Scale) insight scale; * Absence of a current depressive episode (MADRS score \< 21) or suicidal risk (MADRS score item 10 \< 3); * Absence of epileptic pathology; * Chronic obsessive-compulsive disorder defined by a total YBOCS score \> 20, or a subscale score \> 15; * Drug-resistant obsessive-compulsive disorder despite treatment with: 1. at least 2 antidepressants of the IRS type at an effective dose and for a sufficient duration 2. and/or Behavioral and Cognitive therapy for at least 1 year; * Therapeutic stability (antidepressants) for more than 12 weeks without significant improvement. This treatment, at a fixed dose, will be maintained during the study; * Patient aged between 18 and 70 included * Patient who has given his/her informed consent after having received written information on the planned procedure; * Patient benefiting from social security or by benefiting through a third party.
Exclusion criteria
* Woman of childbearing age without effective means of contraception (hormonal/mechanical: oral, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy) * Pregnant or nursing woman; * Patient hospitalized under duress (SPDT, SPDRE); * Patient under guardianship or curatorship; * Patient with another DSM-V Axis 1 diagnosis (Schizophrenic Disorder, Bipolar Disorder, Substance Abuse or Substance Dependence). Generalized anxiety disorder, social phobia, nicotine addiction and history of major depressive episodes are not
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| YBOCS scale | 3,5 months | The primary endpoint corresponds to the change in the score on the YBOCS scale between the inclusion visit (Day 0) and the Day 42 visit. A score of 0 corresponds to the absence of OCD and a score of 40 to maximum severity. |
Countries
France
Contacts
Primary ContactGhina HARIKA-GERMANEAU, Dr
Outcome results
None listed